Abbott appears well-positioned to weather the pandemic with continued revenue growth in diabetes, heart failure devices and molecular diagnostics.
Despite the ongoing pandemic, Abbott Laboratories Inc. reported revenue growth in all four of its main businesses during the first quarter of 2020, including 2.9% organic year-over-year growth in its medical device businesses and 0.7% growth in diagnostics revenues.
“The underlying fundamentals of our business remain strong and our manufacturing and supply chain have been highly resilient,” Abbott CEO Robert Ford said during a 16 April earnings call. “We've...
Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.
German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.
Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.
